Dominik Escher is a former Founder & CEO of ESBATech, a Swiss biotech focusing on next generation antibody drugs. Alcon acquired ESBATech for USD 589 mn in 2009. Subsequently until 2016 Vice President of Alcon R&D. Member of the Global Ophthalmology Leadership and Global Biologics Leadership of Novartis Institutes of Biomedical Research. Since 2002 on the Board of the Swiss Biotech Association.
Current role